Heart Attack Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1008476|
|出版日期||內容資訊||英文 120 Pages
|心臟病發作診斷的全球市場- 成長，趨勢，COVID-19的影響，及預測(2021年∼2026年) Heart Attack Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年05月13日||內容資訊: 英文 120 Pages||
市場成長的主要因素有心血管疾病的流行，它是全球的首要死因，在中低收入國家發病率很高，到2035年大約 45% 的美國人會患有某種心臟病（主要是心臟病發作）。另一方面，成本和缺乏意識等是市場阻礙因素。
The global heart attack diagnostic market is expected to register a CAGR of 7.9% in the forecast period (2021 - 2026).
The COVID-19 pandemic has significantly increased the risk for people suffering from heart diseases, especially those prone to heart attacks, and is more likely to die if not diagnosed on time. Moreover, some of the early symptoms of COVID-19 are aligned with heart attacks, like chest pain, nausea, fatigue, and trouble breathing. In July 2020, a report published by researchers from the University of Alberta Faculty of Medicine and Dentistry discovered a new blood test for predicting heart attack in patients suffering from COVID-19. It proved a relationship between the high risk of COVID-19 in people having cardiovascular diseases. Thus, this ongoing COVID-19 pandemic is going to play a major role in the heart attack diagnostics market.
According to a World Health Organization report, cardiovascular diseases are the main cause of deaths worldwide, and four out of five deaths occur due to cardiovascular diseases, like heart attack and strokes. Furthermore, over 13 million deaths occur in low- and middle-income countries every year, and of these, 85% were due to heart attack and stroke. A report from the American Heart Association says that by 2035, around 45% of Americans may be suffering from some sort of heart disease (mainly heart attack), which may be a major driving force for the heart attack diagnostic market. The major factors contributing to this high number of cardiovascular diseases are hypertension, high blood cholesterol, and smoking. The proven methods for detecting heart attacks are electrocardiograms, blood tests, angiograms, and computerized cardiac tomography. Recently, the US Food and Drug Administration approved a new and high sensitivity test for a protein, Troponin, for the detection of heart attacks, in which Roche and Abbott are the major players.
Although many factors are likely to drive this market to a new height, a few restraining factors, like cost and lack of awareness, may create hindrances in its path. As the market is spread across the world and low-income countries are involved, these diagnostic kits need to be within budget, and people should be aware of them. For instance, the Roche Trop T Sensitivity test kit is available for about USD 52 (2020) in India, which is out of reach for many low-income families and is not easily available.
Rapid Blood Tests like Troponin Test is Expected to Occupy a Significant Share in the Market over the Forecast Period
Over the forecast period, the ECG domain may see some high growth rates in the low- and middle-income countries, while developed countries will observe major growth in the rapid blood test and enzyme-based diagnostics techniques, like Troponin T diagnostic kit and Creatine Kinase MB Isoenzyme (CK-MB) diagnostic technique. These are highly sensitive and rapid tests that give results in an hour or two while current ones provide results in six or seven hours, giving doctors few extra hours, which can be enough to save a patient's life.
Moreover, the developing countries may not be limited to ECG-based tests only, thus, creating a huge market for rapid blood tests due to their huge population. For example, India and China witness millions of deaths every year due to cardiovascular diseases. Electrocardiogram (ECG) is a more complex system that can only be performed if the patient is physically available. At the same time, there are no such limitations for blood and enzyme-based diagnostic techniques. In a country like India where basic healthcare facility is out of reach from most of the population, this kind of blood tests can be performed anywhere in the mobile hospitals. It is observed that the troponin market reached an evaluation of USD 1 billion in 2017, and by 2025, it may become a market of more than USD 2 billion.
North America is Expected to Dominate the Heart Attack Diagnostics Market during the Forecast Period
As per the report by CDC, at every 40 seconds, an American may have a heart attack, and it is one of the expensive conditions treated in US hospitals. According to the American Heart Association, by 2035, around 45% of the United States population are likely to suffer from heart disease, due to factors, like high obesity, high smoking, and unhealthy lifestyle, which lead to heart attack and related issues. Thus, North America is expected to dominate the overall heart attack diagnostics market over the forecast period (2021 - 2026). Other reasons that may be a factor in this will be quality healthcare infrastructure and high scope for innovation.
While in Canada, deaths due to heart attack and cardiovascular diseases are as low as 189 out of 100,000 (2019), out of which the heart attack deaths are very less. Whereas, in the other part of North America, i.e., Mexico, the death rate due to heart attack and cardiovascular diseases are quite high. Furthermore, around 24% of deaths in Mexico are due to cardiovascular diseases, mainly because of the huge consumption of tobacco and alcohol, and poor health infrastructure, among others.
The heart attack diagnostics market is expected to be highly competitive, with several key players in the market. New rapid and portable (flexible) blood and enzyme-based tests may dominate the market and innovations in these domains. Moreover, innovations in the ECG technique may be a game-changer for low-income countries and severe heart-related diseases. Some major players include Siemens Healthcare GmbH, Schiller AG, GE Healthcare, Hitachi Medical Systems, and F Hoffmann-La Roche Ltd.